The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (NASDAQ: VNDA). The commercial-stage ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares are surging Thursday after the company announced plans to broaden its drug ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Terns plans to move to a Phase 2 trial for its TERN-601 small-molecule GLP-1 receptor agonist and will submit the latest data ...

Keith Speights has positions in Pfizer and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Pfizer, and Vertex Pharmaceuticals. The Motley Fool recommends Moderna. The ...

Learn more about whether ACADIA Pharmaceuticals Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on ...

Before the trading day starts we bring you a digest of the key news and events that are likely to move markets. Today we look ...

Indian shares are set to open higher on Tuesday, tracking a rebound in global stocks ahead of the key U.S. inflation data and ...

Learn more about whether Arcellx Inc or Centessa Pharmaceuticals PLC - ADR is a better investment based on AAII's A+ Investor ...